Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Sclerosis and MEN2 Neoplasia in a Female Patient: A Unique Co-Existence with Expanded Immunological Interest and Therapeutical Challenges, before and after Patient's COVID-19 Infection.
Markoglou N, Simeakis G, Alevizaki M, Velonakis G, Chatzistamatiou T, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Stefanis L, Anagnostouli M. Markoglou N, et al. Among authors: spyropoulou vlachou m. Biomedicines. 2022 Nov 8;10(11):2850. doi: 10.3390/biomedicines10112850. Biomedicines. 2022. PMID: 36359367 Free PMC article.
HLA-genotyping by next-generation-sequencing reveals shared and unique HLA alleles in two patients with coexisting neuromyelitis optica spectrum disorder and thymectomized myasthenia gravis: Immunological implications for mutual aetiopathogenesis?
Vakrakou A, Chatzistamatiou T, Koros C, Karathanasis D, Tentolouris-Piperas V, Tzanetakos D, Stathopoulos P, Koutsis G, Spyropoulou-Vlachou M, Evangelopoulos ME, Stefanis L, Stavropoulos-Giokas C, Anagnostouli M. Vakrakou A, et al. Among authors: spyropoulou vlachou m. Mult Scler Relat Disord. 2022 Jul;63:103858. doi: 10.1016/j.msard.2022.103858. Epub 2022 May 8. Mult Scler Relat Disord. 2022. PMID: 35594634
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease.
Kastritis E, Rousakis P, Kostopoulos IV, Gavriatopoulou M, Theodorakakou F, Fotiou D, Dialoupi I, Migkou M, Roussou M, Kanellias N, Tselegkidi MI, Eleutherakis-Papaiakovou E, Papanikolaou A, Gakiopoulou C, Psimenou E, Spyropoulou-Vlachou M, Gatou A, Terpos E, Tsitsilonis O, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Amyloid. 2021 Dec;28(4):259-266. doi: 10.1080/13506129.2021.1971192. Epub 2021 Sep 1. Amyloid. 2021. PMID: 34468250
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M, Karatrasoglou EA, Tselegkidi MI, Ntalianis A, Kanellias N, Eleutherakis-Papaiakovou E, Ntanasis-Stathopoulos I, Gakiopoulou C, Papanikolaou A, Papathoma A, Spyropoulou-Vlachou M, Psimenou E, Stamatelopoulos K, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Amyloid. 2021 Mar;28(1):3-11. doi: 10.1080/13506129.2020.1798224. Epub 2020 Jul 27. Amyloid. 2021. PMID: 32713209
Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy.
Terpos E, Kostopoulos IV, Kastritis E, Ntanasis-Stathopoulos I, Migkou M, Rousakis P, Argyriou AT, Kanellias N, Fotiou D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ziogas DC, Papanota AM, Spyropoulou-Vlachou M, Trougakos IP, Tsitsilonis OE, Paiva B, Dimopoulos MA. Terpos E, et al. Among authors: spyropoulou vlachou m. Hemasphere. 2019 Oct 1;3(6):e300. doi: 10.1097/HS9.0000000000000300. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976475 Free PMC article.
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Kastritis E, Roussou M, Gavriatopoulou M, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Ziogas DC, Fotiou D, Ntanasis-Stathopoulos I, Dialoupi I, Giannouli S, Tsirigotis P, Delimpasi S, Mparmparousi D, Spyropoulou-Vlachou M, Xirokosta A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Blood Adv. 2019 Dec 10;3(23):4095-4103. doi: 10.1182/bloodadvances.2019000539. Blood Adv. 2019. PMID: 31821457 Free PMC article.
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20. Amyloid. 2018. PMID: 30663408
Non-Inherited Maternal Antigens Identify Acceptable HLA Mismatches: A New Policy for the Hellenic Cord Blood Bank.
Panagouli E, Dinou A, Mallis P, Michalopoulos E, Papassavas A, Spyropoulou-Vlachou M, Meletis J, Angelopoulou M, Konstantopoulos K, Vassilakopoulos T, Stavropoulos-Giokas C. Panagouli E, et al. Among authors: spyropoulou vlachou m. Bioengineering (Basel). 2018 Sep 21;5(4):77. doi: 10.3390/bioengineering5040077. Bioengineering (Basel). 2018. PMID: 30248919 Free PMC article.
Resolution of HLA-B*44:02:01G, -DRB1*14:01:01G and -DQB1*03:01:01G reveals a high allelic variability among 12 European populations.
Vidan-Jeras B, Buhler S, Dubois V, Grubic Z, Ivanova M, Jaatinen T, Ligeiro D, Lokki ML, Papasteriades C, Poli F, Spyropoulou-Vlachou M, Tordai A, Viken MK, Wenda S, Nunes JM, Sanchez-Mazas A, Tiercy JM. Vidan-Jeras B, et al. Among authors: spyropoulou vlachou m. Tissue Antigens. 2014 Nov;84(5):459-64. doi: 10.1111/tan.12422. Epub 2014 Sep 11. Tissue Antigens. 2014. PMID: 25209151 Clinical Trial.
28 results